Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-135.57
Price to sales ratio
4.19

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
7274
YDESW
YD Bio Limited - Warrants
0.2561 USD0.00%-22.44%-21.22%-53.44%152.20 M USD
7289
ENGNW
enGene Therapeutics Inc. - Warrants
0.3200 USD0.00%+10.34%+38.17%-60.49%124.60 M USD
7363
CINGW
Cingulate Inc. - Warrants
0.0233 USD0.00%+17.68%+16.50%-45.18%62.13 M USD
7409
ESLAW
Estrella Immunopharma, Inc. - Warrant
0.1000 USD0.00%-26.58%-23.08%+183.29%37.87 M USD

Frequently asked questions about Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

What is the Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock price today?

The current price of Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) is 18.7. Over the past 24 hours, the stock has changed by 0.00%. Follow the FBIOP chart for real-time price dynamics.

What is the stock ticker of Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock?

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock trades under the ticker FBIOP. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock going up?

FBIOP has changed by -6.78% over the last week, -10.53% over the last month, and +124.22% over the last year. Review the chart to see whether the current move is part of a broader trend.

Does Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock release financial reports?

Yes. You can track Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What was Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock net income for the last quarter?

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock reported net income of 110.37 M for the last quarter. The previous quarter showed -3.94 M, which means net income changed by +2903.48%.

How many employees does Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock have?

As of the latest available data, Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has 78 employees. Workforce size can provide additional context about the company's scale and operations.

What is Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock EBITDA?

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock EBITDA is -3.46 M, and its EBITDA margin is -21.6%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock?

You can buy Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock?

Investing in Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the FBIOP chart and related analysis on metatrader.com as part of your research.

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

News